Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07271186 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
A Phase 2 study of Diabetic Kidney Disease (DKD), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT07271186 is a Phase 2 study of Diabetic Kidney Disease (DKD) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 270 participants. The trial reports 20 study locations across 4 states.
The verdict
NCT07271186, a Phase 2 study of Diabetic Kidney Disease (DKD), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times
Conditions Studied
Interventions
- DRUG ALN-ANG3
- DRUG Evinacumab
- DRUG ALN-ANG3 placebo
- DRUG Evinacumab placebo
Study Locations (20)
Florida
- D&H Doral Research Center - Doral
- AGA Clinical Trials - Hialeah
- Convenient Medical Center - Hialeah
- Elixia Hollywood - Hollywood
- D&H Pompano Research Center - Margate
- LCC Medical Research Institute - Miami
- D&H National Research Centers, Inc - Miami
- Regenerate Primary Medical Research, LLC - Miami
- Ocean Blue Medical Research Center - Internal Medicine - Miami Springs
- Innovia Research Center - Miramar
- Bolanos Clinical Research - Pembroke Pines
- D&H Tamarac Research Center - Tamarac
- Metabolic Research Institute - West Palm Beach
California
- Amicis Research Center - Northridge
- Central Coast Nephrology - Salinas
- North America Research Institute - San Dimas
- Amicis Research Center - Santa Clarita
- Amicis Research Center - Valencia
Arkansas
- Applied Research Center of Arkansas - Little Rock
Illinois
- Research by Design, LLC - Internal Medicine - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2026-01-09 |
| Est. Completion | 2028-04-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07271186
The ClinicalTrials.gov registry entry for NCT07271186 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Kidney Disease (DKD) appearing as the primary indexed condition, and to 4 interventions - of which ALN-ANG3 is the first listed.
NCT07271186 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT07271186 about?
NCT07271186 is a clinical study titled "Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease". This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research quest...
What is the current status of trial NCT07271186?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2026-01-09. Estimated completion is 2028-04-07.
What conditions does trial NCT07271186 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease (DKD).
What interventions are being tested in trial NCT07271186?
The interventions under investigation include: ALN-ANG3 (DRUG), Evinacumab (DRUG), ALN-ANG3 placebo (DRUG), Evinacumab placebo (DRUG).
Who is sponsoring clinical trial NCT07271186?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07271186 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease (DKD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.